Mashup Score:9
VJHemOncVJSocial Media Masterclass – Engagement on Twitter - 5 days
Mashup Score:9
Twitter Feed: VJHemOnc
Mashup Score:6
VJHemOncRashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of novel technologies...
-
We spoke to @kanagalshamanna (@MDAndersonNews) at #ASH22, who shared insights into the use of optical genome mapping for characterization of chromoanagenesis and TP53 mutations in MDS patients: 👉 https://t.co/BqaQKenPvl 👈 @ASH_hematology #HemOnc #MDSsm - view on twitter
Mashup Score:5
VJHemOncMagnetisMM-4: elranatamab in combination with other agents for patients with multiple myeloma - 1 week
Mashup Score:5
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some insights into the MagnetisMM-4...
-
#ASH22 | @DrOlaLandgren (@SylvesterCancer) shares some insights into the MagnetisMM-4 trial evaluating elranatamab in combination with other agents for patients with multiple myeloma. Watch here: 🎥: https://t.co/CH9xjbiOjT @ASH_hematology #MMsm #ImmunoOnc #HemOnc #Myeloma - view on twitter
Mashup Score:5
VJHemOncAshutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, comments on patient...
-
Find out more about the current challenges with selecting patients with AL amyloidosis for autologous transplantation in our interview with @awechalekar of @uclh: 🎥: https://t.co/MNxW6m0RK3 #ASH22 #Amyloidosis #BMTsm #HemOnc - view on twitter
Mashup Score:4
VJHemOncWhen should patients with intermediate-risk AML be indicated for alloSCT? - 1 week
Mashup Score:4
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, shares some results from a study which evaluated whether...
-
Christoph Röllig (@Medizin_TUD) discusses the results of a study assessing the optimal time for alloSCT indication in patients with intermediate-risk AML: 👉 https://t.co/vbuZwqk5Ja 👈 @ASH_hematology #ASH22 #AMLsm #LeuSM #BMTsm #HemOnc - view on twitter
Mashup Score:3
VJHemOncPost-ASH 2022 iwMDS | VJHemOnc - 1 day
Mashup Score:3
Expert-led presentations & discussions on key abstracts in myelodysplastic syndromes (MDS) from ASH 2022 The Post-ASH 2022 iwMDS Virtual Workshop was held on 12...
-
🚨 If you want to find out the latest updates in MDS from ASH 2022, take a look at the on-demand content from our recent virtual workshop! All presentations & panel discussions can be found here: 👉https://t.co/JOaLCThjbh👈 #MDSsm #HemOnc #ImmunoOnc https://t.co/JOaLCThjbh👈 - view on twitter
Mashup Score:3
VJHemOncGenomic factors underlying resistance to immunotherapy in newly diagnosed multiple myeloma - 5 days
Mashup Score:3
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the results of a study which...
-
Find out more about genomic factors underlying resistance to immunotherapy in patients with NDMM in our exclusive interview with @FrancescoMaura4 of @SylvesterCancer: 🎥: https://t.co/ndx50QvKbN #ASH22 #MMsm #HemOnc #ImmunoOnc - view on twitter
Mashup Score:3
VJHemOncPrimary analysis of the TRANSFORM study: liso-cel vs SOC as second-line treatment for R/R LBCL - 1 week
Mashup Score:3
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, shares the results from the primary analysis of the...
-
Manali Kamdar (@CUCancerCenter) shares the results from the primary analysis of the Phase III TRANSFORM study at #ASH22: 👉https://t.co/hwH4e9IwGl👈 @ASH_hematology #LymSM #HemOnc #ImmunoOnc #CARTcell #tcellrx #LBCL - view on twitter
Mashup Score:3
VJHemOncJeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, shares some insights into current immunotherapeutic agents being explored for the...
-
Jeremy Abramson (@MGHCancerCenter) shares some insights into the importance of CAR-T therapy & bispecifics in the treatment of #DLBCL: 👉https://t.co/4qP8X4EBos👈 #HemOnc #LymSM #WorldCancerDay #ImmunoOnc #CloseTheCareGap - view on twitter
Mashup Score:3
VJHemOncPhase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL - 1 week
Mashup Score:3
Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College London Hospital, London, UK, briefly summarizes preliminary data from a Phase...
-
🎥 @drparagjasani of @uclh shares some preliminary data from a Phase I trial evaluating NVG-111, a ROR1xCD3 BiTE, as monotherapy or in combination with ibrutinib in R/R CLL & MCL: 👉https://t.co/4q2ho3UTPH👈 @ASH_hematology #ASH22 #LeuSM #LymSM #CLLsm #MCLsm #ImmunoOnc #HemOnc - view on twitter
Watch this VJSocial Media Masterclass to learn how to engage on Twitter effectively and appropriately alongside your clinical...
Ready to make the most of #SocialMedia in 2023 as a #healthcareprofessional? Check out VJSocial!📱 #HemOnc experts @Mohty_EBMT @sanamloghavi @tobyeyre82 & @Dr_AmerZeidan discuss all things #socialmediaengagement in our latest masterclass💡 👉 https://t.co/vuC5OQxCIH https://t.co/vuC5OQxCIH - view on twitter